| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CMC1 |
| Uniprot No | Q7Z7K0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-106aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMALDPAD QHLRHVEKDV LIPKIMREKA KERCSEQVQD FTKCCKNSGV LMVVKCRKEN SALKECLTAY YNDPAFYEEC KMEYLKEREE FRKTGIPTKK RLQKLPTSM |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CMC1重组蛋白的3篇代表性文献示例(注：以下内容为模拟虚构，仅供参考格式)：
---
1. **文献名称**: *Recombinant CMC1 Protein Expression and Its Role in Mitochondrial Calcium Uptake*
**作者**: Smith J, et al.
**摘要**: 本研究利用大肠杆菌系统成功表达并纯化了重组CMC1蛋白，验证其与MICU1/MICU2调控亚基的相互作用。通过体外钙离子结合实验证实，CMC1是线粒体钙摄取复合物的核心结构组分，对维持心肌细胞线粒体钙稳态具有关键作用。
---
2. **文献名称**: *Structural Characterization of Human CMC1 and Implications for Cardiac Dysfunction*
**作者**: Lee H, et al.
**摘要**: 通过冷冻电镜技术解析了重组人源CMC1蛋白的高分辨率结构，揭示了其跨膜结构域特征。功能实验表明CMC1突变体导致线粒体钙超载，与扩张型心肌病的病理机制相关，为靶向治疗提供了结构基础。
---
3. **文献名称**: *CMC1 Recombinant Protein as a Therapeutic Target in Ischemia-Reperfusion Injury*
**作者**: Garcia R, et al.
**摘要**: 研究在小鼠模型中评估了重组CMC1蛋白的干预效果。结果显示，外源性CMC1可通过调节线粒体钙信号通路减少心肌缺血再灌注损伤，提示其作为潜在心脏保护剂的临床应用价值。
---
注：实际文献需通过PubMed/Google Scholar检索关键词“CMC1 recombinant protein”或“CMC1 mitochondrial calcium”获取。如需真实文献，请提供更多研究背景或具体应用方向。
CMC1 recombinant protein, derived from the CMC1 (Cardiac Membrane Component 1) gene, is a biologically engineered protein with emerging significance in cardiovascular and musculoskeletal research. CMC1 is a transmembrane protein predominantly expressed in cardiac and skeletal muscle tissues, where it plays a role in maintaining structural integrity and facilitating cell-matrix interactions. It is associated with the regulation of cellular adhesion and signaling pathways, particularly those involving integrins and extracellular matrix components. Dysregulation of CMC1 has been implicated in pathological conditions such as cardiomyopathy and muscular dystrophy, making it a potential therapeutic target.
The recombinant CMC1 protein is produced using heterologous expression systems, such as mammalian cell lines (e.g., HEK293 or CHO cells) or bacterial systems (e.g., E. coli), depending on the required post-translational modifications. Purification typically involves affinity chromatography followed by rigorous quality control to ensure bioactivity and stability. Its recombinant form retains the functional domains of the native protein, enabling applications in vitro and in vivo studies.
In research, CMC1 recombinant protein is utilized to investigate mechanisms of muscle cell adhesion, tissue repair, and disease progression. It serves as a critical tool for developing cell culture models, screening drug candidates, and exploring gene therapy strategies. Additionally, it has potential diagnostic value as a biomarker for muscle-related disorders. Ongoing studies focus on optimizing its therapeutic delivery and evaluating its efficacy in preclinical models, highlighting its versatility in bridging basic science and clinical innovation.
×
